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This study prospectively assessed the impact of treatment modality, virus load, and CD4
cell count of !50 cells/mm3 on human immunodeficiency virus disease progression. The in-
cidence rate of new AIDS disease or death was 54.8 (95% confidence interval, 48.7–59.9) per
100 person-years of follow-up. Independent predictors related to progression were latest CD4
cell count (relative risk [RR], 0.84/10 mm3 higher; ), latest hemoglobin level (RR,P ! .0001
0.79/g/L higher; ), Pneumocystis carinii pneumonia prophylaxis (RR, 0.49;P ! .0001 P !
), latest body mass index (RR, 0.93/kg/m2 higher; ), latest virus load (RR, 1.11/.0001 Pp .002
log10 higher; ), and intensity of treatment (RR, 1.82, ; RR 2.27, ;Pp .03 Pp .004 P ! .0001
RR 2.46, ; RR 2.33 ; 5.10, , respectively, for 4, 3, 2, 1, or no drugsPp .0001 P ! .0006 P ! .0001
vs.5 drugs). Although reverse causality cannot be excluded, more intense antiviral treatment
appears to decrease the risk of progression in immunocompromised patients.
Although highly active antiretroviral therapy (HAART) has
noticeably and significantly reduced the morbidity and mortality
associated with human immunodeficiency virus (HIV) type 1
infection [1, 2], virologic treatment failure is frequent [3, 4]. The
prognostic value of plasma HIV-1 RNA and CD4 cell count for
clinical progression was originally measured in antiretroviral un-
treated or minimally treated patient populations [5, 6].
Data from several cohorts indicate that CD4 cell counts may
remain stable or continue to increase in patients on HAART,
despite a rebound in plasma HIV-1 RNA levels [7–9]. Because
the level of immunosuppression or immunocompetence deter-
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mines disease progression, CD4 cell count may be a better
predictor for progression than plasma HIV-1 RNA levels for
patients receiving HAART. On the other hand, a treatment
benefit independent of both CD4 cell count and virus load was
observed when patients receiving protease inhibitors (PIs) were
compared with patients not receiving PI-containing therapies,
although both virus load and CD4 cell count remained signif-
icant independent factors associated with disease progression
[10]. Furthermore, treatment discontinuation in patients with
virologic failure leads to rapid increases in virus load and de-
clining CD4 cell count, which provides further evidence of a
treatment benefit despite virologic failure [11, 12]. However,
continuation of antiretroviral treatment in the presence of de-
tectable levels of viral replication carry the risk of further viral
evolution toward higher levels of resistance [13] and the de-
velopment or worsening of existing drug toxicities. Thus, it is
important to investigate the relationship between plasma HIV-
1 RNA levels, CD4 cell counts, treatment modality, and disease
progression in greater detail. From a clinical perspective, the
management options for the increasing proportion of patients
experiencing significant immunologic and virologic failure while
receiving HAART are sparse; multidrug combinations of 6
drugs are frequently used without clinical endpoint data to
support this practice [14, 15].
A previous analysis of the EuroSIDA cohort indicated that
disease progression in patients with low CD4 cell counts was
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related inversely to intensity of treatment. The incidence rates
of clinical progression were 38–78 per 100 person-years of pa-
tient follow-up, according to the intensity of treatment, even
though all patients had CD4 cell counts of 50 cells/mm3 [16].
In another study, the incidence of AIDS-defining illnesses was
significantly lower if patients were receiving HAART in each
CD4 cell strata examined, and this was confirmed for 7 of 8
individual diagnoses [17]. In these 2 studies, the impact of
plasma HIV-1 RNA and type of HAART treatment on disease
progression could not be established. Historically, the majority
of patients receiving HAART received PIs.
Our objective for the present analysis was to assess the impact
of the treatment modality in combination with virus load and
CD4 cell count on disease progression in patients with CD4
cell counts of 50 cells/mm3. In addition to CD4 cell count
and virus load, we looked at hemoglobin levels [17–19], body
mass index (BMI), and the use of prophylaxis for opportunistic
infections.
Subjects and Methods
Subjects and setting. The EuroSIDA study includes 18500 pa-
tients from 64 centers across Europe and Israel. Details of the study
have been published elsewhere [17, 20]. In brief, patients16 years
old with CD4 cell count of 500 cells/mm3 (restriction applies to
cohorts 1–3) were recruited into the study. Information is collected
from patient case notes onto a standardized data collection form
at baseline and every 6 months thereafter. Data collected at each
follow-up visit include the latest weight and hemoglobin measure-
ments, all CD4 lymphocyte counts measured at the participating
site since last the follow-up, and all virus load measurements (with
the method used and the lower limit of detection). The date of
starting and stopping each antiretroviral drug is recorded, as are
drugs for prophylaxis against opportunistic infections. Dates of
diagnosis of all AIDS-defining illnesses are also recorded as defined
by the 1993 Centers for Disease Control and Prevention clinical
definition of AIDS [21]. Members of the coordinating office visit
all centers to ensure correct patient selection and accurate data
collection. Follow-up for this analysis is to summer 2000.
Statistical analyses. Incidence rates of clinical progression (new
AIDS or death) were calculated as number of events per 100 per-
son-years of follow-up [22] within various strata of current calendar
year, presence of a previous AIDS diagnosis, latest CD4 cell count
(cells/mm3), latest virus load (copies/mL) measurement, latest he-
moglobin (g/L) measure, latest BMI (kg/m2), number of drugs re-
ceived 3 months previously, total drugs ever taken, and current use
of Pneumocystis carinii pneumonia (PCP) and/or Mycobacterium
avium complex (MAC) prophylaxis. The basic time units used were
months. A given month for a given subject contributed to the
person-years at risk if the most recent CD4 cell count and virus
load were measured 6 months earlier, the most recent CD4 cell
count was !50 cells/mm3, and the subject was under active follow-
up in the EuroSIDA. Thus, person-months contributed by a given
subject were not necessarily consecutive, depending on availability
of virus load and CD4 cell counts and on whether CD4 cells were
!50 cells/mm3. Eligible patients had 1 month of follow-up; the
first such month was the baseline date for that patient.
When we considered the association with clinical progression of
the number of drugs being taken, patient follow-up was allocated
to the treatment regimen 3 months previously rather than that in
the same month. This lag was used because of the tendency for all
drugs to be stopped immediately before death and occasionally
upon occurrence or diagnosis of an AIDS disease, and we wished
to study the effect of the drug regimen on risk of death and not
the converse. We calculated confidence intervals (CIs) for the in-
cidence rates by using a normal approximation (if there were !20
events, Poisson distribution was used). Poisson regression models
were used to assess predictors of disease progression.
In addition to grouping patients by number of drugs received 3
months earlier, we also grouped patients according to whether they
were receiving a PI, a nonnucleoside reverse-transcriptase inhibitor
(NNRTI), or nucleoside reverse-transcriptase inhibitors (NRTIs)
only. We used generalized estimating equations with the Poissonmod-
els when we considered rates of new AIDS disease or death because
we included multiple AIDS events for the same subject [23]. PCP
prophylaxis was defined as use of cotrimoxazole, trimethoprim-
sulfamethoxazole, pentamidine, dapsone, or atovaquone. MAC pro-
phylaxis was defined as the use of (any) ethambutol, rifabutin, or
clarithromycin/azithromycin. All statistical analyses were performed
by using SAS software (version 6.12; SAS Institute). Poisson re-
gression was performed with PROC GENMOD software (SAS
Institute).
Results
Patient population. In total, 1106 patients satisfied the entry
criteria for this study and yielded 808.0 person-years of follow-
up. Table 1 shows the characteristics of the patients at the time
they first met eligibility criteria (referred to as baseline). Of the
subjects, 69% had a baseline date before January 1998, 83%
were male, and 46% were infected through homosexual contact.
The median CD4 cell count was 27 cells/mm3; 53% of patients
entered the study with CD4 cell counts of !30 cells/mm3. The
median virus load at baseline was 4.8 log10 copies/mL (63,000
copies/mL), and 56% of patients had 150,000 HIV copies/mL
at study entry. Table 1 also shows the distributions for he-
moglobin and BMI categories.
At baseline, 122 (11%) patients were not receiving any an-
tiretroviral treatment (table 2), 68% were receiving 3 drugs
(10% were receiving 5 drugs), 727 (74%) were receiving 1
PIs at baseline, 112 (11%) were receiving 1 NNRTIs, and 222
(23%) were receiving NRTIs only. Of those receiving5 drugs,
58% were receiving ritonavir, compared with 43% receiving 4
drugs, and 18% receiving 3 drugs. Because the EuroSIDA da-
tabase does not include drug doses, it is not possible to report
whether ritonavir was being used only as a pharmacologic en-
hancer of drug levels of other PIs or at therapeutic levels. The
majority of subjects (52%) had ever received 3–5 drugs; 29%
had ever received 6 drugs (table 2). Opportunistic infection
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Table 1. Patient characteristics ( ).np 1106
Characteristic
No. (%)
of patients
Baseline date
Before Jan 1998 670 (69)
Jan 1998–Dec 1998 172 (18)
Jan 1999–Dec 1999 113 (12)
After Dec 1999 23 (2)
Female 183 (17)
Mode of exposure
Homosexual 505 (46)
Injected drug use 257 (23)
Heterosexual 251 (23)
Other 93 (8)
Age, median years (interquartile range) 38 (33–45)
Previous AIDS diagnosis 689 (62)
CD4 cell count, cells/mm3
!10 209 (19)
10–29 381 (34)
30–50 516 (47)
Baseline HIV load, copies/mL
!10,000 181 (16)
10,000–49,999 309 (28)
50,000–299,999 341 (31)
300,000 275 (25)
Baseline hemoglobin level,a g/L
!10 109 (11)
10–11 261 (27)
12–13 366 (37)
14 242 (25)
Baseline body mass index,b kg/m2
!18.0 43 (10)
18.0–21.9 170 (40)
22.0–25.9 163 (39)
26.0 45 (11)
NOTE. HIV, human immunodeficiency virus.
a Data available for 978 patients.
b Data available for 421 patients.
Table 2. Antiretroviral treatment at baseline
and previous drug history ( ).np 1106
Treatment history
No. (%)
of patients
No. of current drugs
0 122 (11)
1 54 (5)
2 182 (16)
3 440 (40)
4 195 (18)
5 113 (10)
Total different drugs taken
0–2 217 (20)
3–5 570 (52)
6–8 256 (23)
9 63 (6)
prophylaxis use increased with increasing antiretroviral drug
use: for patients receiving 0, 1, 2, 3, 4, or 5 drugs, PCP pro-
phylaxis was used by 66%, 74%, 72%, 84%, 89%, and 92%,
respectively, and MAC infection prophylaxis was used by 16%,
23%, 22%, 24%, 34%, and 39%, respectively.
Clinical progression. For all follow-up comparisons, the me-
dian/mean (interquartile range) months since the most recent
CD4 cell count was 1/1.7 months (0–3/0–6 months). For virus
load the equivalent values were 1/1.5 months (0–2/0–6 months).
In all, 443 clinical events occurred during the follow-up period.
Of these, 190 (42.9%) were progressions to new AIDS events in
patients with AIDS at baseline, 178 (40.2%) were deaths, and 75
(16.9%) were first AIDS-defining events. Thus, the overall inci-
dence rate (AIDS-defining illnesses and death) was 54.8 (95%
CI, 49.7–59.9) per 100 person-years of follow-up; the overall rate
for death was 22.1 (95% CI, 18.9–25.3). The most common clin-
ical events were esophageal candidiasis (20%), cytomegalovirus
retinitis (12%), non-Hodgkin lymphoma (9%), PCP (8%), Kaposi
sarcoma (7%), progressive multifocal leukoencephalopathy (6%),
and disseminated MAC infection (5%).
Both the overall rate of clinical disease progression (a new
AIDS-defining illness or death) and the death rate decreased
with each additional drug received 3 months earlier (141.9 [95%
CI, 114.4–169.4] vs. 26.9 [95% CI, 18.6–35.2] for patients re-
ceiving 0 vs.5 drugs for overall rate; 72.3 [95% CI, 52.6–92.0]
vs. 6.7 [95% CI, 2.5–10.9] for death rate) (table 3). In contrast,
the rates did not change consistently by number of drugs ever
taken. Patients with an AIDS diagnosis (prior to the month
under consideration) had a higher overall rate (61.6 [95% CI,
55.2–68.0] vs. 38.7 [95% CI, 30.8–46.6]). The rate increased with
decreasing latest CD4 cell count (36.1 [95% CI, 29.1–43.1] for
30 vs. 86.5 [95% CI, 73.7–99.3] for CD4 cell counts of 10
cells/mm3) and with increasing latest virus load (33.5 [95% CI,
23.5–43.5] vs. 77.2 [95% CI, 64.9–89.5] for !10,000 vs.300,000
copies/mL).
The AIDS-defining illness or death rate also increased as he-
moglobin and BMI decreased (24.9 [95% CI, 17.4–32.4] vs. 132.7
[95% CI. 108.7–156.7] for hemoglobin levels 14 g/L vs. !10 g/
L; 43.5 [95% CI, 22.2–64.8] vs. 135.4 [95% CI, 105.7–165.1] for
BMI 26 kg/m2 vs. !18 kg/m2). When we considered death as
an end point, the rate increased or decreased in a similar manner.
Patients receiving PCP prophylaxis experienced a lower rate of
new AIDS-defining illnesses or death (46.3 [95% CI, 41.3–51.3]
vs. 110.5 [95% CI, 90.6–130.3]), whereas the rate was slightly
higher in patients receiving MAC prophylaxis (62.1 [95% CI,
52.0–72.0] vs. 51.9 [95% CI, 46.0–57.8]). The event rate did not
differ substantially by current (i.e., the month of follow-up under
consideration) calendar year.
Clinical progression according to latest virus load, CD4 cell
count, or hemoglobin level in combination with number of drugs
received. The combined effect of number of drugs received
3 months previously with latest virus load, CD4 cell count, and
hemoglobin measurements on event rates is illustrated in figure
1. This figure shows how the number of drugs affect clinical
progression according to each of the other variables. The as-
sociation between the number of drugs and clinical progression
was generally consistent across the strata of other variables.
Predictors of disease progression. We next estimated the
effect of all of the variables on disease progression to clinical
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Table 3. Distribution of person-years of follow-up, numbers of disease progression events, and number of
deaths with rates per 100 person-years.
Characteristic
Person-years
of follow-up
New AIDS or death Death
No. Rate 95% CI No. Rate 95% CI
Calendar year (current)
Before Jan 1998 336.8 194 57.6 49.9–65.6 74 22.0 17.1–26.9
Jan 1998–Dec 1998 221.7 116 52.3 42.7–61.9 50 22.5 16.2–28.8
Jan 1999–Dec 1999 191.0 98 51.3 41.1–61.5 35 18.3 7.97–18.23
After Dec 1999 58.5 35 59.8 40.0–79.6 19 32.5 17.9–47.1
Previous AIDS diagnosis
Yes 570.2 351 61.6 55.2–68.0 161 28.2 23.8–32.6
No 237.8 92 38.7 30.8–46.6 17 71.5 68.1–74.9
Latest CD4 cell count, cells/mm3
!10 201.2 174 86.5 73.7–99.3 79 39.3 30.6–47.7
10–29 324.0 167 51.5 43.7–59.3 60 18.5 13.8–23.2
30–50 282.8 102 36.1 29.1–43.1 39 13.8 9.5–18.1
Latest HIV load, copies/mL
!10,000 128.5 43 33.5 23.5–43.5 24 18.7 11.4–26.0
10,000–49,999 211.2 89 42.1 33.4–50.8 39 18.5 12.7–24.3
50,000–299,999 274.0 161 58.8 49.7–67.9 64 23.3 17.6–29.0
300,000 194.3 150 77.2 64.9–89.5 51 26.2 19.0–33.4
Latest hemoglobin level, g/L
!10 88.2 117 132.7 108.7–156.7 73 82.8 63.8–101.8
10–11 195.2 148 75.8 63.6–88.0 59 30.2 22.5–37.9
12–13 258.3 90 34.8 27.6–42.0 31 12.0 7.8–16.2
14 168.8 42 24.9 17.4–32.4 8 4.7 1.4–8.0
Latest body mass index, kg/m2
!18.0 59.1 80 135.4 105.7–165.1 45 76.1 53.9–98.3
18.0–21.9 196.0 122 62.2 51.2–73.2 42 21.4 14.9–27.9
22.0–25.9 155.3 66 42.5 32.3–52.7 23 14.8 8.8–20.8
26.0 36.8 16 43.5 22.2–64.8 8 21.7 6.6–36.8
No. of different drugs taken in prior 3 months
0 71.9 102 141.9 114.4–169.4 52 72.3 52.6–92.0
1 44.3 28 63.2 39.8–86.6 10 22.6 8.6–36.6
2 118.0 67 56.8 43.2–70.4 29 24.6 15.7–33.5
3 258.5 130 50.3 41.7–58.9 51 19.7 14.3–25.1
4 166.7 76 45.6 35.4–55.8 26 15.6 9.6–21.6
5 148.7 40 26.9 18.6–35.2 10 6.7 2.5–10.9
Total different drugs taken
0–2 61.0 56 91.8 67.8–115.8 19 31.1 17.1–45.1
3–5 301.0 158 52.5 44.3–60.7 60 19.9 14.9–24.9
6–8 269.9 125 46.3 38.2–54.4 62 23.0 17.3–28.7
9 176.1 104 59.1 47.8–70.4 37 21.0 14.2–27.8
Pneumocystis carinii pneumonia prophylaxis
Yes 700.3 324 46.3 41.3–51.3 110 15.7 12.8–18.6
No 107.7 119 110.5 90.6–130.3 68 63.1 48.1–78.1
Mycobacterium avium complex prophylaxis
Yes 233.5 145 62.1 52.0–72.0 52 22.3 16.3–28.3
No 574.5 298 51.9 46.0–57.8 126 21.9 18.1–25.7
NOTE. CI, confidence interval; HIV, human immunodeficiency virus.
events or death in univariable and multivariable (adjusted for
all variables in the table, except BMI) models (table 4). Cal-
endar time of entry into the analysis was not associated with
progression to clinical events or death. After adjusting for all
other variables, a previous AIDS diagnosis was associated only
with death (rate ratio, 2.81; 95% CI, 1.55–5.10; ) andPp .007
not with clinical progression. A latest CD4 cell count of 10
cells/mm3 was associated with a lower rate ratio for both clinical
progression and death, with a rate ratio of 0.84 (95% CI, 0.78–
0.91; ) and 0.83 (95% CI, 0.75–0.93; ), re-P ! .0001 Pp .003
spectively. In contrast, a 1-log higher latest virus load was less
significant and was associated with clinical progression only,
with a rate ratio of 1.11 (95% CI, 1.01–1.23; ). BothPp .03
latest hemoglobin and BMI remained highly significantly as-
sociated with clinical progression ( and , re-P ! .002 Pp .0009
spectively). Only hemoglobin remained a significant predictor
for death ( ). We also considered weight, but, in thisP ! .0001
analysis, BMI had a stronger association with risk of disease
progression and death.
In contrast to the number of different drugs taken, the effect
of the number of drugs in the regimen was striking. For clinical
progression, receiving 4 versus 5 drugs was associated with
an increased ratio of 1.82 (95% CI, 1.21–2.72; ), andPp .004
the rate ratios continued to increase with fewer drugs, with a
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Figure 1. Overall event rate (new AIDS-defining illnesses or death) per 100 person-years of follow-up by number of antiviral drugs and latest
virus load (A), CD4 cell count (B), and hemoglobin measurement (C).
rate ratio of 5.10 (95% CI, 3.29–2.92; ) for patientsP ! .0001
receiving no drugs. Similarly, for death, the rate ratio for pa-
tients receiving 4 versus 5 drugs increased to 2.36 (95% CI,
1.06–5.26; ), and the rate ratio increased to 13.2 (95%Pp .04
CI, 6.05–28.8; ) for patients receiving no drugs. Pa-P ! .0001
tients receiving PCP prophylaxis had a profoundly reduced rate
ratio for clinical progression (relative risk [RR], 0.49; 95% CI,
0.38–0.63; ) and for progression to death (RR, 0.27;P 1 .0001
95% CI, 0.18–0.39; ), whereas those receiving MACP ! .0001
prophylaxis were at a slightly raised risk of clinical progression
( ).Pp .05
We also assessed the effect of class of drugs used (PI and
NNRTI, PI but not NNRTI, NNRTI but not PI, and NRTI
only) but this was not independently associated with risk of
progression. Similarly, total time receiving antiviral therapy,
total time receiving PI, total time receiving NNRTIs, total time
receiving antiviral therapy with HIV-1 RNA level measured as
1500 copies (which relies on virus load actually being measured
and thus is only a crude proxy for the true time with virus load
actually 1500 copies/mL) were not significant for either end-
point. In a further analysis, we also included in the model a
variable indicating whether or not one of the drugs was rito-
navir, and this was not significantly independently associated
with risk of disease progression. Results in table 4 were similar
when we allowed CD4 cell count and virus load values to re-
main current for only 3 months instead of 6 months (np
; 633.3 person-years; adjusted rate ratio for AIDS or death1048
for virus load, 1.13; ) and for CD4 cell count (0.84;Pp .02
). We also fitted the number of drugs taken 3 monthsPp .0001
earlier as a continuous variable. The rate ratios per 1 less drug
were 1.30 ( ) for new AIDS or death and 1.54 (P ! .0001 P !
) for death as end point. There was no significant inter-.0001
action between calendar time and these associations ( ).P 1 .1
Finally, we repeated the analysis by including the number of
drugs in use 6 months rather than 3 months previously. For
new events, the rate ratio for patients using 4, 3, 2, 1, and 0
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Table 4. Results from Poisson regression models of predictors of disease progression and death shown as rate ratio on the basis of 710.5
person-years of follow-up with hemoglobin level known.
Characteristic
Rate of clinical events Rate of clinical events
Univariate Adjusted Univariate Adjusted
Calendar year, per year 1.01 (0.92–1.12); .78 1.00 (0.99–1.01); .86 0.94 (0.79–1.11); .46 1.01 (1.00–1.03); .10
Previous AIDS diagnosis 1.45 (1.12–1.88); .005 1.22 (0.92–1.63); .17 3.35 (2.05–5.53); !.0001 2.81 (1.55–5.10); .0007
Latest CD4 cell count, 10 cells/mm3 higher 0.77 (0.71–0.84); !.0001 0.84 (0.78–0.91); !.0001 0.73 (0.65–0.83); !.001 0.83 (0.75–0.93); .001
Latest virus load, log copy/mL higher 1.27 (1.16–1.40); !.0001 1.11 (1.01–1.23); .03 1.14 (0.98–1.32); .09 0.90 (0.77–1.04); .17
Latest hemoglobin levels, g/L higher 0.75 (0.71–0.79); !.0001 0.79 (0.76–0.83); !.0001 0.65 (0.59–0.72); !.0001 0.70 (0.64–0.76); !.0001
Latest BMI, kg/m2 highera 0.86 (0.82–0.90); !.0001 0.93 (0.89–0.97); .002 0.83 (0.77–0.90); !.0001 0.95 (0.88–1.02); .14
Total different drugs taken, per extra drug 0.98 (0.94–1.02); .31 1.04 (0.99–1.10); .12 0.97 (0.91–1.03); .27 1.09 (1.01–1.17); .03
No. of different drugs taken 3 months previously
0 5.21 (3.46–7.85); !.0001 5.10 (3.29–7.92); !.0001 11.5 (5.64–23.6); !.0001 13.2 (6.05–28.8); !.0001
1 2.64 (1.60–4.31); .0002 2.33 (1.43–3.78); .0006 3.67 (1.40–9.58); .008 4.18 (1.62–10.7); .003
2 2.32 (1.48–3.63); .0003 2.46 (1.46–3.86); .0001 3.97 (1.84–8.58); .0004 4.85 (2.16–10.8); !.0001
3 2.05 (1.38–3.03); .0004 2.27 (1.53–3.35); !.0001 2.97 (1.43–6.23); .004 3.46 (1.60–7.39); .002
4 1.79 (1.15–2.77); .01 1.82 (1.21–2.72); .004 2.39 (1.09–5.26); .03 2.36 (1.06–5.26); .04
5 1.00 1.00 1.00 1.00
Receiving PCP prophylaxis 0.42 (0.33–0.53); !.0001 0.49 (0.38–0.63); !.0001 0.22 (0.16–0.30); !.0001 0.27 (0.18–0.39); !.0001
Receiving MAC prophylaxis 1.17 (0.92–1.48); .19 1.28 (1.00–1.65); .05 0.98 (0.68–1.39); .90 1.17 (0.81–1.70); .40
NOTE. Data are rate ratio (95% confidence interval) and P value. BMI, bone mass index; MAC, Mycobacterium avium complex; PCP, Pneumocystis carinii
pneumonia.
a Based on 447.2 person-years of follow-up.
drugs relative to 5 drugs was 1.43 ( ), 1.99 (Pp .07 Pp
), 1.32 ( ), 1.04 ( ), and 3.00 ( ),.0003 Pp .21 Pp .90 P 1 .0001
respectively. For death as outcome, the corresponding figures
were 1.99 ( ), 3.42 ( ), 2.83 ( ), 2.10Pp .07 Pp .0003 Pp .006
( ), and 6.42 ( ).Pp .09 P ! .0001
Discussion
In this analysis of patients with CD4 cell counts of !50 cells/
mm3, we found that disease progression and death are predicted
by the latest CD4 cell count, hemoglobin measurement, BMI
while receiving PCP prophylaxis, and number of drugs in the
treatment regimen. AIDS status was a predictor for death only,
and plasma HIV-1 RNA was a predictor for clinical progression
only. Thus, our data suggest that it is helpful to continue an-
tiviral therapy and prophylactic therapy, despite severe im-
munodeficiency and regardless of plasma HIV RNA levels, and
that the benefit due to each therapy is independent of the other.
The association between the number of antiviral drugs used
could indicate that receiving 5 drugs may be more beneficial
than the standard 3-drug combination therapy for this patient
population. An alternative explanation is that there is a “reverse
causality,” such that the number of drugs a person is taking is
a reflection of health status and that those patients able to
manage more drugs have a lower risk of disease and death than
those patients not able to take any or many drugs. This may
also contribute to the strong effect attributable to PCP pro-
phylaxis in our analysis.
In an attempt to reduce this reverse causality effect, we used
the number of antiviral drugs a person was taking 3 months
before the period of risk under consideration, rather than at the
latest time. The greater this lag period, the less we would expect
to see the influence of reverse causality; so, in a secondary anal-
ysis, this lag time was increased to 6 months. Although the mag-
nitude of the association was reduced (as would be expected
regardless of the direction of causality), a significant association
was maintained, which suggests that a reverse causality effect is
unlikely to fully explain the association.
The intensity of antiviral treatment appears to provide a
treatment effect over and above that we can model with the
surrogate markers of CD4 cells, virus load, use of prophylaxis,
and the additional clinical markers of hemoglobin level and
BMI. This effect may be due to the treatment itself and, as
such, may be related to its potency or to the patient’s adherence
or alternatively be due to some effect of the treatment that we
cannot yet measure. It is possible that in the identification of
patients taking more than the standard (3-drug combination)
antiviral therapy, we selected for patients who had a longer
treatment phase and who lived longer for as yet unknown rea-
sons. Our additional analyses (time on antiviral therapy), how-
ever, do not support this hypothesis.
Another finding of interest is that in patients with very low
CD4 cell counts, the absolute number of CD4 cells does mat-
ter. Thus, patients with CD4 cell counts of !10 cells/mm3 fare
worse than patients with CD4 cell counts of 10 cells/mm3. Of
the 2 surrogate markers, CD4 cell count was a stronger pre-
dictor for disease progression. Plasma HIV-1 RNA did not
predict death in this patient population ( ). This is inPp .17
agreement with previous studies that found CD4 cell count to
be a better predictor for clinical progression in patients with
very advanced HIV disease [19, 24].
In previous studies, hemoglobin was found to be a prognostic
marker [18, 19, 25–27]. Anemia may be a marker of ongoing,
as yet undiagnosed opportunistic disease or a marker of general
immune activation. Weight was not previously associated with
progression, and it is of interest that BMI (a measure of weight
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standardized for height) was a prognostic marker in this study
of patients with very advanced disease. It is likely that BMI is
a better indicator of health status than weight alone. It will be
of interest to confirm this finding in other studies.
Treatment management of patients with advanced HIV disease
is becoming increasingly complex with issues of drug toxicity and
requirement for comedications playing a significant role. In ad-
dition, these patients frequently have had extensive prior treat-
ment experience and are experiencing virologic failure.
In our study, 84% of the patients had plasma HIV-1 RNA
levels 110,000 copies/mL, and 29% had been exposed to 6
drugs. Our data raise the possibility that intensive antiretroviral
treatment (5 antiretroviral drugs) is of clinical benefit in this
patient population. However, these results are based on follow-
up in an observational cohort rather than by randomized as-
signment to various treatment modalities. Thus, care should be
taken in the interpretation of these findings. It will be of interest
to compare our results with those of randomized trials that are
currently underway to address the issue of treatment intensity
in persons with advanced HIV disease and treatment failure.
Our study spans from January 1998 to the first quarter of 2000.
Although the availability of treatment choices may have in-
creased during the study period, this is unlikely to have influ-
enced our findings as calendar time was not identified as a
predictor in any of the models tested.
The finding of an independent treatment benefit is in agreement
with findings in prior studies [7, 8, 10, 16, 17], indicating a clinical
and/or immunologic benefit to continuing treatment despite vi-
rologic failure and (possibly) viral drug resistance. This treatment
effect could be due to a residual activity of the regimen in spite
of decreased drug susceptibility, changes in virus characteristics
due to accumulation of drug resistance-associated mutations (de-
creased fitness or replicative capacity and/or changes in patho-
genicity), or to nonantiviral effects of the inhibitors. For example,
HIV-1 PIs inhibit proteases of Candida albicans [28] and P. carinii
[29] in in vitro models. In addition, they may be protective for
CD4 cells against apoptosis [30].
We found that use of PCP prophylaxis was associated with
a markedly reduced risk of new AIDS and/or deathaA. Al-
though this likely partly reflects the efficacy of prophylaxis, it
could also be due to reverse causality, as discussed above. How-
ever, in contrast, use of MAC prophylaxis was associated with
a somewhat raised rate of new AIDS/death, which was of bor-
derline statistical significance ( ). This could reflect somePp .05
residual confounding, with persons given such prophylaxis be-
ing at increased risk of new AIDS/death due to factors not
captured and adjusted for in the multivariable model. Ran-
domized trials have shown clinical benefit for MAC prophy-
laxis, and our results do not contradict the current recommen-
dations for MAC prophylaxis [31].
Patients with low CD4 cell counts are at a high risk of clinical
progression. Unfortunately, many such persons have experi-
enced previous treatment failures, potentially have drug-resis-
tant virus, and may not have many therapeutic options avail-
able to them. Although it is difficult to exclude the possibility
that some of the association is due to reverse causality—with
healthier people able to tolerate more drugs—our results sug-
gest that keeping these patients on antiviral treatment never-
theless is likely to be better than not giving any treatment at
all. Although the risk-benefit evaluation should also include the
risk for continued evolution of resistance [13, 32] and of pos-
sible long-term drug toxicities, our findings add further evi-
dence that the risk-benefit ratio for clinical progression weighs
in favor of treatment continuation rather than interruption in
patients with virologic failure.
EuroSIDA Study Group Members
Study group members are shown by country, with national
coordinators in italics. Austria: N. Vetter (Pulmologisches Zen-
trum der Stadt Wien, Vienna); Belgium: N. Clumeck, P. Her-
mans, B. Sommereijns, (Saint-Pierre Hospital, Brussels) and R.
Colebunders (Institut of Tropical Medicine, Antwerp); Czech
Republic: L. Machala and H. Rozsypal (Faculty Hospital Bu-
lovka, Prague); Denmark: J. Nielsen, J. Lundgren, T. Benfield,
and O. Kirk (Hvidovre Hospital) and J. Gerstoft, T. Katzen-
stein, B. Røge, and P. Skinhøj (Rigshospitalet, Copenhagen),
and C. Pedersen (Odense University Hospital); France: C. Kat-
lama and C. Rivie`re (Hoˆpital de la Pitie´-Salpe´tie`re) and J.-P.
Viard (Hoˆpital Necker-Enfants Malades, Paris), T. Saint-Marc
(Hoˆpital Edouard Herriot), P. Vanhems (University Claude
Bernard, Lyon), and C. Pradier (Hoˆpital de l’Archet, Nice);
Germany: M. Dietrich and C. Manegold (Bernhard-Nocht-In-
stitut for Tropical Medicine), and J. van Lunzen (Eppendorf
Medizinische Kernklinik, Hamburg), V. Miller and S. Stasz-
ewski (J. W. Goethe University Hospital, Frankfurt), F.-D.
Goebel (Medizinische Poliklinik, Munich), B. Salzberger (Univ-
ersita¨t Ko¨ln, Cologne), Ju¨rgen Rockstroh (Medizinische Univ-
ersita¨tsklinik, Bonn); Greece: P. Gargalianos, H. Sambatakou,
and J. Perdios (Athens General Hospital), and G. Stergiou, G.
Panos, G. Boulmetis, and M. Astriti, (1st IKA Hospital, Ath-
ens); Hungary: D. Banhegyi (Szent La´slo´ Hospital, Budapest);
Ireland: F. Mulcahy (St. James’s Hospital, Dublin); Israel: I.
Yust and D. Turner (Ichilov Hospital, Tel Aviv), S. Pollack and
Z. Ben-Ishai (Rambam Medical Center, Haifa), Z. Bentwich
(Kaplan Hospital, Rehovot), S. Maayan (Hadassah University
Hospital, Jerusalem); Italy: S. Vella, A. Chiesi (Istituto Super-
iore di Sanita, Rome); F. Suter and A. Cremaschi (Ospedale
Riuniti, Bergamo), R. Pristera´ (Ospedale Generale Regionale,
Bolzano), F. Mazzotta and F. Vichi (Ospedale S. Maria An-
nunziata, Florence), B. DeRienzo and A. Bedini (Universita` di
Modena), A. Chirianni and V. Montesarchio (Presidio Ospe-
daliero A. D. Cotugno, Naples), V. Vullo and P. Santopadre
(Universita` di Roma La Sapienza) and C. Arrici, P. Franci, P.
Narciso, A. Antinori and M. Zaccarelli (Ospedale Spallanzani,
Rome), A. Lazzarin and R. Finazzi (Ospedale San Raffaele)
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and A. D’Arminio Monforte (Ospedale L. Sacco, Milan); Lux-
embourg: R. Hemmer and T. Staub (Centre Hospitalier, Lux-
embourg); The Netherlands: P. Reiss (Academisch Medisch
Centrum bij de Universiteit van Amsterdam); Norway: J.
Bruun, A. Mæland, and V. Ormaasen (Ulleva˚l University Hos-
pital, Oslo); Poland: B. Knysz and J. Gasiorowski (Medical
University, Wroslaw), A. Horban (Centrum Diagnostyki i Ter-
apii AIDS, Warszawa), R. Rogowska-Szadkowska (Medical
University, Bialystok), A. Boron-Kaczmarska (Medical Uni-
versity, Szczecin), M. Beniowski (Osrodek Diagnostyki i Terapii
AIDS, Chorzow), H. Trocha (Medical University, Gdansk);
Portugal: F. Antunes (Hospital Santa Maria), K. Mansinho
(Hospital de Egas Moniz), and R. Proenca (Hospital Curry
Cabral, Lisbon); Spain: J. Gonza´lez-Lahoz, R. Polo, and V.
Soriano (Hospital Carlos III, Madrid), B. Clotet, A. Jou, J.
Conejero, and C. Tural (Hospital Germans Trias i Pujol, Ba-
dalona), J. Gatell and J. Miro´ (Hospital Clinic I Provincial,
Barcelona); Sweden: A. Blaxhult (Karolinska Hospital), B. Hei-
demann (So¨dersjukhuset), P. Pehrson (Huddinge Sjukhus,
Stockholm); Switzerland: B. Ledergerber and R. Weber (Uni-
versity Hospital, Zu¨rich), P. Francioli and A. Telenti (Centre
Hospitalier Universitaire Vaudois, Lausanne), B. Hirschel and
V. Soravia-Dunand (Hospital Cantonal Universitaire de Ge-
neve, Geneva); United Kingdom: S. Barton (St. Stephen’s
Clinic, Chelsea, and Westminster Hospital), A. M. Johnson and
D. Mercy (University College London Medical School), A.
Phillips, C. Loveday, M. A. Johnson, A. Mocroft, D. Wilson,
T. Drinkwater, A. Dykoff and D. Ross (Royal Free and Uni-
versity College Medical School), A. Pinching and J. M. Parkin
(Medical College of Saint Bartholomew’s Hospital), J. Weber,
D. Churchill, and G. Scullard (Imperial College School of Med-
icine at St. Mary’s, London), M. Fisher (Royal Sussex County
Hospital, Brighton), and R. Brettle (City Hospital, Edinburgh).
Steering committee. J. Nielsen (chair), N. Clumeck, M.
Dietrich, J. M. Gatell, A. Horban, A. Johnson, C. Katlama,
B. Ledergerber, C. Loveday, A. Phillips, P. Reiss, and S. Vella.
Coordinating center staff. J. Lundgren (project leader), I.
Gjørup, T. Benfield, O. Kirk, A. Mocroft, D. Mollerup, M.
Nielsen, A. Sørensen, H. Buch, and L. Teglbjærg.
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